The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Minocycline treatment in acute stroke: An open-label, evaluator-blinded study
Abstract
BACKGROUND: Ischemic animal model studies have shown a neuroprotective effect of minocycline. OBJECTIVE: To analyze the effect of minocycline treatment in human acute ischemic stroke. METHODS: We performed an open-label, evaluator-blinded study. Minocycline at a dosage of 200 mg was administered orally for 5 days. The therapeutic window of time was 6 to 24 hours after onset of stroke. Data from NIH Stroke Scale (NIHSS), modified Rankin Scale (mRS), and Barthel Index (BI) were evaluated. The primary objective was to compare changes from baseline to day 90 in NIHSS in the minocycline group vs placebo. RESULTS: One hundred fifty-two patients were included in the study. Seventy-four patients received minocycline treatment, and 77 received placebo. NIHSS and mRS were significantly lower and BI scores were significantly higher in minocycline-treated patients. This pattern was already apparent on day 7 and day 30 of follow-up. Deaths, myocardial infarctions, recurrent strokes, and hemorrhagic transformations during follow-up did not differ by treatment group. CONCLUSIONS: Patients with acute stroke had significantly better outcome with minocycline treatment compared with placebo. The findings suggest a potential benefit of minocycline in acute ischemic stroke.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wu, D. C., Jackson-Lewis, V., Vila, M., Tieu, K., Teismann, P., Vadseth, C., Choi, D.-K., Ischiropoulos, H., & Przedborski, S. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-05-01763.2002 · Cited by 1,183
Inhibition of autoimmune encephalomyelitis by a tetracycline
Popovic, N., Schubart, A., Goetz, B. D., Zhang, S., Linington, C., & Duncan, I. D. (2002) · Annals of Neurology · doi:10.1002/ana.10092 · Cited by 295
Cited by
Minocycline: Far beyond an Antibiotic
Garrido‐Mesa, N., Zarzuelo, A., & Gálvez, J. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12139 · Cited by 935
Matrix metalloproteinases in the brain and blood–brain barrier: Versatile breakers and makers
Rempe, R. G., Hartz, A. M., & Bauer, B. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16655551 · Cited by 721
The biphasic function of microglia in ischemic stroke
Ma, Y., Wang, J., Wang, Y., & Yang, G.-Y. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.005 · Cited by 655
Minocycline and Neurodegenerative Diseases
Kim, H.-S., & Suh, Y.-H. (2009) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.09.040 · Cited by 447
Levkovitz, Y., Mendlovich, S., Riwkes, S., Braw, Y., Levkovitch-Verbin, H., Gal, G., Fennig, S., Treves, I., & Kron, S. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.08m04666yel · Cited by 387
Neurogenesis and Inflammation after Ischemic Stroke: What is Known and Where We Go from Here
Tobin, M. K., Bonds, J. A., Minshall, R. D., Pelligrino, D. A., Testai, F. D., & Lazarov, O. (2014) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2014.130 · Cited by 310
Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease
Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 306
Microglia–blood vessel interactions: a double-edged sword in brain pathologies
Dudvarski Stankovic, N., Teodorczyk, M., Ploen, R., Zipp, F., & Schmidt, M. H. H. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1524-y · Cited by 301
Evaluation of excess significance bias in animal studies of neurological diseases
Tsilidis, K. K., Panagiotou, O. A., Sena, E. S., Aretouli, E., Evangelou, E., Howells, D. W., Salman, R. A.-S., Macleod, M. R., & Ioannidis, J. P. A. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001609 · Cited by 295
Neuroprotection for Ischaemic Stroke: Translation from the Bench to the Bedside
Sutherland, B. A., Minnerup, J., Balami, J. S., Arba, F., Buchan, A. M., & Kleinschnitz, C. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00770.x · Cited by 259
Sex differences in the brain: Implications for behavioral and biomedical research
Choleris, E., Galea, L. A. M., Sohrabji, F., & Frick, K. M. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.07.005 · Cited by 214
Neural stem cell therapy for subacute and chronic ischemic stroke
Boese, A. C., Le, Q.-S. E., Pham, D., Hamblin, M. H., & Lee, J.-P. (2018) · Stem Cell Research & Therapy · doi:10.1186/s13287-018-0913-2 · Cited by 205
Sex differences in neuroinflammation and neuroprotection in ischemic stroke
Spychala, M. S., Honarpisheh, P., & McCullough, L. D. (2017) · Journal of Neuroscience Research · doi:10.1002/jnr.23962 · Cited by 127
Minocycline development for acute ischemic stroke
Fagan, S. C., Cronic, L. E., & Hess, D. C. (2011) · Translational Stroke Research · doi:10.1007/s12975-011-0072-6 · Cited by 100
The Translational Potential of Microglia and Monocyte-Derived Macrophages in Ischemic Stroke
Wicks, E. E., Ran, K. R., Kim, J. E., Xu, R., Lee, R. P., & Jackson, C. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.897022 · Cited by 92
Rapamycin‐mediated mouse lifespan extension: Late‐life dosage regimes with sex‐specific effects
Strong, R., Miller, R. A., Bogue, M., Fernandez, E., Javors, M. A., Libert, S., Marinez, P. A., Murphy, M. P., Musi, N., Nelson, J. F., et al. (2020) · Aging Cell · doi:10.1111/acel.13269 · Cited by 92
Minocycline treatment for HIV-associated cognitive impairment: Results from a randomized trial
Sacktor, N., Miyahara, S., Deng, L., Evans, S., Schifitto, G., Cohen, B. A., Paul, R., Robertson, K., Jarocki, B., Scarsi, K., et al. (2011) · Neurology · doi:10.1212/wnl.0b013e31822f0412 · Cited by 87
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
Minocycline: a neuroprotective agent for hypoxic-ischemic brain injury in the neonate?
Buller, K. M., Carty, M. L., Reinebrant, H. E., & Wixey, J. A. (2009) · Journal of Neuroscience Research · doi:10.1002/jnr.21890 · Cited by 73
Randomized trial of minocycline in the treatment of HIV-associated cognitive impairment
Nakasujja, N., Miyahara, S., Evans, S., Lee, A., Musisi, S., Katabira, E., Robertson, K., Ronald, A., Clifford, D. B., & Sacktor, N. (2013) · Neurology · doi:10.1212/wnl.0b013e31827b9121 · Cited by 67
Should Stroke Trials Adjust Functional Outcome for Baseline Prognostic Factors?
The Optimising the Analysis of Stroke Trials (OAST) Collaboration (2009) · Stroke · doi:10.1161/strokeaha.108.519207 · Cited by 64
Lyu, Y., Meng, Z., Hu, Y., Jiang, B., Yang, J., Chen, Y., Zhou, J., Li, M., & Wang, H. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1394932 · Cited by 42
Accelerated Aging during Chronic Oxidative Stress: A Role for PARP-1
Boesten, D. M. P. H. J., de Vos-Houben, J. M. J., Timmermans, L., den Hartog, G. J. M., Bast, A., & Hageman, G. J. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/680414 · Cited by 37
Chauhan, P., Kakkar, A. K., Singh, H., & Gautam, C. S. (2021) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2020.1838276 · Cited by 12
Metadata
- Authors
- Lampl, Y., Boaz, M., Gilad, R., Lorberboym, M., Dabby, R., Rapoport, A., Anca-Hershkowitz, M., & Sadeh, M.
- Venue
- Neurology
- Published
- 2007-10-02
- Volume
- 69
- Issue
- 14
- Pages
- 1404-1410
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2136686417
- Cited by
- 440
- References
- 2
- FWCI
- 17.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
